Literature Title

First Author

Type

Publication Year

Publication Journal

Brief Summary

Clinical Practice Pearl

Reference #

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

Garvey

Original Research

2022

Nature Medicine

Once-weekly subcutaneous semaglutide enhances weight loss and patient-reported quality of life outcomes in obese patients. Weight loss in the semaglutide group was 11% more than placebo. However, the trial primarily focuses on patient-reported outcomes, necessitating further research to understand broader clinical implications. The mechanism for quality-of-life improvements and the impact of SGLT2 inhibitors require exploration. Larger studies are needed to assess GLP-1 receptor agonists’ utility.

Semaglutide was superior to placebo in weight loss in obese patients

11

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.

Ghusn

Retrospective Original Research

2022

JAMA Network

Adult with a BMI of 27+, receiving 3 - 6 months of semaglutide injections, achieved significant weight loss: 6.7 kg (5.9%) at 3 months and 12.3 kg (10.9%) at 6 months. Patients with type 2 diabetes had lower weight loss rates. Strengths include real-world data and a sizable sample. Limitations include the absence of a control group and potential recall bias.

Semaglutide is safe and effective in reducing weight in real-world settings

12

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

The STEP 3 Randomized Clinical Trial

Wadden

Original Research

2021

JAMA Network

Obese non-diabetic adults received once-weekly subcutaneous semaglutide + intensive behavioral therapy and an initial low-calorie diet achieved significantly greater weight loss over 68 weeks compared to placebo, with a mean body weight change of −16.0% vs. −5.7% in placebo group. Gastrointestinal adverse events were more common with semaglutide, emphasizing the need for long-term sustainability assessment.

Semaglutide + intensive behavioral therapy + initial low-calorie diet leads to weight loss in non-diabetic individuals with overweight or obesity

13

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

Ahren

Original Investigation Original Research

2017

The Lancet

Once-weekly subcutaneous semaglutide, outperformed sitagliptin in improving glycemic control and reducing body weight among patients with type 2 diabetes inadequately controlled on metformin, thiazolidinediones, or both. Semaglutide demonstrated superior efficacy without significant safety concerns, making it a promising add-on treatment for this patient population.

Semaglutide showed superiority in efficacy over sitagliptin

14